Advances in the prediction and treatment of recurrent pancreatic cancer / 医学研究生学报

ABSTRACT

Patients with pancreatic adenocarcinoma who underwent surgical resection have poor prognosis, with the recurrence rate of over 80% within two years. Currently, the treatment of recurrent pancreatic cancer is still in the exploratory phase, and the efficacy is only limited to chemotherapy. In addition, there are differences in the efficacy of different chemotherapy schemes, and there is no unified chemotherapy scheme. Meanwhile, new radiotherapy and surgical treatment have been proposed for the treatment of recurrent pancreatic cancer, but its efficacy is yet to be confirmed. This paper summarizes the factors to predict postoperative recurrence, various chemotherapy schemes and new radiotherapy methods, reviews and analyzes the effectiveness of surgical treatment on recurrent pancreatic cancer.